Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Other Non-Current Assets (2019 - 2025)

Vivos Therapeutics' Other Non-Current Assets history spans 7 years, with the latest figure at $228000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $228000.0 for Q4 2025, up 5.56% from a year ago — trailing twelve months through Dec 2025 was $228000.0 (up 5.56% YoY), and the annual figure for FY2025 was $228000.0, up 5.56%.
  • Other Non-Current Assets for Q4 2025 was $228000.0 at Vivos Therapeutics, up from $211000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $374648.0 in Q2 2021 to a low of $211000.0 in Q3 2025.
  • The 5-year median for Other Non-Current Assets is $308000.0 (2023), against an average of $307259.8.
  • The sharpest move saw Other Non-Current Assets rose 15.21% in 2021, then plummeted 30.19% in 2025.
  • Year by year, Other Non-Current Assets stood at $356000.0 in 2021, then increased by 5.06% to $374000.0 in 2022, then dropped by 17.91% to $307000.0 in 2023, then decreased by 29.64% to $216000.0 in 2024, then grew by 5.56% to $228000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $228000.0, $211000.0, and $255000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.